Burning Rock Biotech (BNR) Net Margin (2019 - 2026)

Burning Rock Biotech (BNR) has reported Net Margin for 8 consecutive years, with 16.18% the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Margin fell 603.0% year-over-year to 16.18%; the TTM figure through Mar 2026 stood at 11.57% (up 3409.0% YoY), while the FY2025 annual figure was 2.81%, up 1320.0% from the prior year.
• Net Margin came in at 16.18% for Q1 2026 at Burning Rock Biotech, down from 12.17% in the prior quarter.
• The five-year high for Net Margin was 6.53% in Q2 2025, with the low at 200.36% in Q2 2022.
• Average Net Margin over 5 years is 89.02%, with a median of 89.72% recorded in 2023.
• Across the five-year window, Net Margin sank 4034 bps in 2022 and surged 11063 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 152.02% in 2022, then advanced by 12 bps to 133.97% in 2023, then surged by 51 bps to 65.55% in 2024, then soared by 81 bps to 12.17% in 2025, then tumbled by 33 bps to 16.18% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 16.18%, 12.17%, and 12.74% for Q1 2026, Q4 2025, and Q3 2025 respectively.